Education
About Us
Working with TipRanks
Follow Us
InnoCan Pharma (TSE:INNO)
:INNO
INNO Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.16 - C$0.33
Previous CloseN/A
Volume118.77K
Average Volume (3M)90.38K
Market Cap
$60.26M
Enterprise ValueC$60.25M
Total Cash (Recent Filing)$214.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Jun 02, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding286,938,260
10 Day Avg. Volume34,889
30 Day Avg. Volume90,378
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.37
Price to Cash Flow (P/CF)-9.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.03
Enterprise Value/Ebitda-72.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
InnoCan Pharma News
PremiumCompany Announcements
Innocan Pharma Announces $1 Million Debenture Offering to Tamar Innovest
PremiumCompany Announcements
Innocan Pharma Secures Indian Patent for Liposomal CBD Injection
PremiumCompany Announcements
Innocan Pharma’s Subsidiary Achieves Safety and Sales Milestones
PremiumCompany Announcements
InnoCan Pharma Secures C$635K in Private Placement
PremiumCompany Announcements
Innocan Pharma Announces C$700K Private Placement
PremiumCompany Announcements
InnoCan Pharma Achieves Key Milestones in 2024---
Options Prices
Currently, No data available
---
Ownership Overview
5.42% Insiders
―
Mutual Funds
― Other Institutional Investors
94.58% Public Companies and
Individual Investors
INNO FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was C$0.16 and its highest was C$0.33 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is $60.26M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Jun 02, 2025 which is in 64 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on Nov 20, 2024. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 286,938,260 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in TSE:INNO
---
Company Description
InnoCan Pharma
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
---
Technical Analysis
---